Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF

British Journal of Ophthalmology

Volumn 94, Issue 11, 2010, Pages 1533-1539

  Kernt, Marcus ^a   Neubauer, A S ^a   Liegl, R G ^a   Hirneiss, C ^a   Alge, C S ^a   Wolf, A ^a   Ulbig, M W ^a   Kampik, A ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; BENZENESULFONIC ACID DERIVATIVE; MEMBRANE PROTEIN; MESSENGER RNA; PIGF PROTEIN, HUMAN; PYRIDINE DERIVATIVE; VASCULOTROPIN A;

ARTICLE; CELL VIABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; LIGHT EXPOSURE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGED; CELL CULTURE; CELL SURVIVAL; DOSE RESPONSE; FEMALE; HUMAN; LIGHT; METABOLISM; MIDDLE AGED; RETINA MACULA DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; BENZENESULFONATES; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LIGHT; MACULAR DEGENERATION; MEMBRANE PROTEINS; MIDDLE AGED; PLATELET-DERIVED GROWTH FACTOR; PYRIDINES; RETINAL PIGMENT EPITHELIUM; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78149485833     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.182162     Document Type: Article

References (55)

1. Ehrlich R, Harris A, Kheradiya NS, et al. Age-related macular degeneration and the aging eye. Clin Interv Aging 2008;3:473-82.
2. Cruickshanks KJ, Klein R, Klein BE. Sunlight and age-related macular degeneration. the Beaver Dam Eye Study. Arch Ophthalmol 1993;111:514-18. (Pubitemid 23116899)
3. Cruickshanks KJ, Klein R, Klein BE, et al. Sunlight and the 5-year incidence of early age-related maculopathy: the beaver dam eye study. Arch Ophthalmol 2001;119:246-50.
4. Tomany SC, Cruickshanks KJ, Klein R, et al. Sunlight and the 10-year incidence of age-related maculopathy: the beaver dam eye study. Arch Ophthalmol 2004;122:750-7. (Pubitemid 38596256)
5. Fine SL, Berger JW, Maguire MG, et al. Age-related macular degeneration. N Engl J Med 2000;342:483-92.
6. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med 2008;358:2606-17.
7. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A 1995;92:10457-61.
8. Aiello LP. Targeting intraocular neovascularization and edema - one drop at a time. N Engl J Med 2008;359:967-9.
9. van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-13.
10. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
12. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005;36:336-9.
13. Freyberger H, Brocker M, Yakut H, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 2000;108:106-9.
14. Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci 1994;35:3649-63.
15. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2004;242:91-101.
16. Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29. (Pubitemid 36207453)
17. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
18. Diago T, Pulido JS, Molina JR, et al. Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration. Mayo Clin Proc 2008;83:231-4.
19. Kernt M, Staehler M, Stief C, et al. Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment. Acta Ophthalmol 2008;86:456-8.
20. Kernt M, Neubauer AS, Liegl R, et al. Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression. J Cataract Refract Surg 2009;35:354-62.
21. Algvere PV, Marshall J, Seregard S. Age-related maculopathy and the impact of blue light hazard. Acta Ophthalmol Scand 2006;84:4-15.
22. Algvere PV, Seregard S. Age-related maculopathy: pathogenetic features and new treatment modalities. Acta Ophthalmol Scand 2002;80:136-43. (Pubitemid 34406844)
23. Holz FG, Pauleikhoff D, Klein R, et al. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 2004;137:504-10.
24. Barishak YR. In vitro behaviour of the pigmented cells of the retina and uvea of the adult human eye. Acta Ophthalmol (Copenh) 1960;38:339-46.
25. Flood MT, Gouras P, Kjeldbye H. Growth characteristics and ultrastructure of human retinal pigment epithelium in vitro. Invest Ophthalmol Vis Sci 1980;19:1309-20.
26. Nilsson SE, Sundelin SP, Wihlmark U, et al. Aging of cultured retinal pigment epithelial cells: oxidative reactions, lipofuscin formation and blue light damage. Doc Ophthalmol 2003;106:13-16. (Pubitemid 36355966)
27. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63.
28. Roth F, Bindewald A, Holz FG. Keypathophysiologic pathways in age-related macular disease. Graefes Arch Clin Exp Ophthalmol 2004;242:710-16. (Pubitemid 39242849)
29. Holz FG, Bellmann C, Margaritidis M, et al. Patterns of increased in vivo fundus autofluorescence in the junctional zone of geographic atrophy of the retinal pigment epithelium associated with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237:145-52. (Pubitemid 29137302)
30. Schutt F, Bergmann M, Holz FG, et al. Isolation of intact lysosomes from human RPE cells and effects of A2-E on the integrity of the lysosomal and other cellular membranes. Graefes Arch Clin Exp Ophthalmol 2002;240:983-8.
31. Hageman GS, Luthert PJ, Victor Chong NH, et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 2001;20:705-32.
32. Starita C, Hussain AA, Patmore A, et al. Localization of the site of major resistance to fluid transport in Bruch's membrane. Invest Ophthalmol Vis Sci 1997;38:762-7.
33. Moshfeghi DM, Blumenkranz MS. Role of genetic factors and inflammation in age-related macular degeneration. Retina 2007;27:269-75.
34. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 2006;82:99-110.
35. Zhou J, Cai B, Jang YP, et al. Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. Exp Eye Res 2005;80:567-80.
36. Yanagi Y, Inoue Y, Iriyama A, et al. Effects of yellow intraocular lenses on light-induced upregulation of vascular endothelial growth factor. J Cataract Refract Surg 2006;32:1540-4. (Pubitemid 44262467)
37. Kernt M, Hirneiss C, Neubauer AS, et al. Protective effect of blue light-absorbing IOLs on the human retinal pigment epithelium. Ophthalmologe 2010 Feb;107:150-7.
38. Kliffen M, van der Schaft TL, Mooy CM, et al. Morphologic changes in age-related maculopathy. Microsc Res Tech 1997;36:106-22.
39. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996;80:363-6.
40. Crocker DJ, Murad TM, Geer JC. Role of the pericyte in wound healing. An ultrastructural study. Exp Mol Pathol 1970;13:51-65.
41. Schlingemann RO, Oosterwijk E, Wesseling P, et al. Aminopeptidase a is a constituent of activated pericytes in angiogenesis. J Pathol 1996;179:436-42.
42. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Faseb J 2004;18:338-40.
43. Jo N, Mailhos C, Ju M, et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006;168:2036-53.
44. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003;83:835-70.
45. Spaide RF. Rationale for combination therapy in age-related macular degeneration. Retina 2009;29(6 Suppl):S5-7.
46. Adnane L, Trail PA, Taylor I, et al. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597-612.
47. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8. (Pubitemid 46094197)
48. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
49. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34.
50. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
51. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-12.
52. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
53. Houben R, Voigt H, Noelke C, et al. MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol Cancer Ther 2009;8:433-40.
54. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 2005;5:188-96.
55. Peyman GA, Fiscella R, Conway M. Combination angiostatic therapies: current status. Retina 2009;29(6 Suppl):S18-20.